ABSTRACT
Mutations in HNRNPA1 encoding heterogeneous nuclear ribonucleoprotein (hnRNP) A1 are a rare cause of amyotrophic lateral sclerosis (ALS) and multisystem proteinopathy (MSP). hnRNPA1 is part of the group of RNA-binding proteins (RBPs) that assemble with RNA to form ribonucleoproteins. hnRNPs are a major subclass of evolutionarily conserved RBPs that are primarily concentrated in the nucleus and are heavily involved in pre-mRNA splicing, mRNA stability and transcriptional/translational regulation. During times of stress, standard translational programming is interrupted, and hnRNPs, mRNA, and other RBPs condense in the cytoplasm, forming liquid-liquid phase separated (LLPS) membraneless organelles termed stress granules (SGs). SGs are central to the pathogenesis of (neuro-)degenerative diseases, including ALS and inclusion body myopathy (IBM). hnRNPs and other RBPs are critical components of SGs. Indeed, the link between SGs, hnRNPs, and neurodegenerative diseases has been established by the identification of additional mutations in RBPs that affect SG biology, including FUS, TDP-43, hnRNPA1, hnRNPA2B1, and TIA1, each of which can directly lead to ALS, IBM and other related neurodegenerative diseases. Here, we report and characterize four novel HNRNPA1 mutations and two known HNRNPA1 mutations, previously reported as being causal for ALS, in a broad spectrum of patients with hereditary motor neuropathy (HMN), ALS, and myopathy. Our results show the different effects of mutations on hnRNPA1 fibrillization, liquid-liquid phase separation, and SG dynamics, indicating the possibility of different underlying pathomechanisms for HNRNPA1 mutations with a possible link to the clinical phenotypes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Association Belge contre les Maladies Neuromusculaire (ABMM) - Aide a la Recherche ASBL (2017-2018/05), the EU FP7/2007-2013 under grant agreement number 2012-305121 (NEUROMICS), the EU Horizon 2020 program (Solve-RD under grant agreement No 779257), J.P.T. funding: Howard Hughes Medical Institute, the National Institutes of Health (R35NS097974), the St. Jude Research Collaborative on Membraneless Organelles, and the NINDS P01 NS069539. A.K. is supported by National Science Centre Poland grant no. 2016/23/B/NZ3/02035. S.M.M. is supported by the NINDS P01 NS069539. J.B. is supported by a Senior Clinical Researcher mandate of the Research Fund - Flanders (FWO) under grant agreement number 1805016N. J.S. funding: Target ALS, Packard Foundation for ALS research, ALS Association, The G. Harold and Leila Y. Mathers Charitable Foundation, and NIH grant R01GM099836. L.G. funding: Ellison Medical Foundation/American Federation for Aging Research fellowship, Alzheimer's Association Research fellowship, and a Target ALS Springboard Fellowship. C.M.F. funding: NIH grants T32GM008275 and F31NS111870. A.F.F. funding: NIH grants T32AG00255 and F31NS087676. Research reported in this manuscript was in part supported by the NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director under Award Number U01HG007708. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All families consented to genetic diagnostic follow-up within their respective hospital/diagnostic center. The ethical review board of the University of Antwerp approved this study
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
FUNDING This work was supported by the Association Belge contre les Maladies Neuromusculaire (ABMM) - Aide à la Recherche ASBL (2017-2018/05), the EU FP7/2007-2013 under grant agreement number 2012-305121 (NEUROMICS), the EU Horizon 2020 program (Solve-RD under grant agreement No 779257), J.P.T. funding: Howard Hughes Medical Institute, the National Institutes of Health (R35NS097974), the St. Jude Research Collaborative on Membraneless Organelles. A.K. is supported by National Science Centre Poland grant no. 2016/23/B/NZ3/02035. S.M.M. is supported by the NINDS P01 NS069539. J.B. is supported by a Senior Clinical Researcher mandate of the Research Fund - Flanders (FWO) under grant agreement number 1805016N. J.S. funding: Target ALS, Packard Foundation for ALS research, ALS Association, The G. Harold and Leila Y. Mathers Charitable Foundation, and NIH grant R01GM099836. L.G. funding: Ellison Medical Foundation/American Federation for Aging Research fellowship, Alzheimer’s Association Research fellowship, and a Target ALS Springboard Fellowship. C.M.F. funding: NIH grants T32GM008275 and F31NS111870. A.F.F. funding: NIH grants T32AG00255 and F31NS087676. Research reported in this manuscript was in part supported by the NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director under Award Number U01HG007708. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Data Availability
Sequence datasets of the six families are not available due to privacy concerns.
